JAK3 and rheumatoid arthritis: Tofacitinib is reported to have functional selectivity for heterodimer pairs involving JAK1 and/or JAK3.4, 5 Other JAK inhibitors with ongoing or completed late development RA clinical trials include baricitinib, upadacitinib, and filgotinib.